Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

LGC Biosearch Technologies A/S Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading... Loading... Loading... Loading...

1.0 Bankruptcy Risk  2018 2019/3 2019 2020/3 2020 2021/3 2021 2022/3 2022 2023/3 2023 2024/3 2024e N/A 2025e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5%   Bankruptcy risk   0.6% 0.5% 1.7% 0.5% 0.5% 0.4% 4.6% 4.2%   Credit score (0-100)   98 99 73 99 99 99 46 48   Credit rating   AA AA A AAA AAA AAA BBB BBB   Credit limit (mDKK)   1.7 2.7 0.1 8.6 10.2 9.9 0.0 0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1.0 Income statement (mDKK)  2018 2019/3 2019 2020/3 2020 2021/3 2021 2022/3 2022 2023/3 2023 2024/3 2024e N/A 2025e N/A Net sales   28 42 104 101 118 106 106 106   Gross profit   15.8 23.2 70.9 50.5 60.1 46.3 0.0 0.0   EBITDA   5.8 11.0 51.8 23.9 25.3 14.4 0.0 0.0   EBIT   3.6 8.3 48.1 17.2 15.4 3.5 0.0 0.0   Pre-tax profit (PTP)   3.2 8.0 47.9 16.1 14.8 3.3 0.0 0.0   Net earnings   3.8 8.0 35.6 12.6 11.7 2.6 0.0 0.0   Pre-tax profit without non-rec. items   3.2 8.0 47.9 16.1 14.8 3.3 0.0 0.0     See the entire income statement 1.0 Balance sheet (mDKK)  2018 2019/3 2019 2020/3 2020 2021/3 2021 2022/3 2022 2023/3 2023 2024/3 2024e N/A 2025e N/A Tangible assets total   7.9 9.6 12.8 45.0 41.8 40.3 0.0 0.0   Shareholders equity total   9.3 17.4 53.0 65.6 77.3 79.9 79.4 79.4   Interest-bearing liabilities   15.3 7.5 2.0 4.7 10.2 2.1 0.0 0.0   Balance sheet total (assets)   29.7 34.0 74.0 87.6 103 99.6 79.4 79.4   Net Debt   9.3 3.2 -26.4 -2.5 -3.5 -14.4 -76.6 -76.6     See the entire balance sheet 1.0 Volume  2018 2019/3 2019 2020/3 2020 2021/3 2021 2022/3 2022 2023/3 2023 2024/3 2024e N/A 2025e N/A Net sales   28 42 104 101 118 106 106 106   Net sales growth   0.0% 49.7% 148.2% -2.2% 16.3% -10.5% 0.0% 0.0%   Gross profit   15.8 23.2 70.9 50.5 60.1 46.3 0.0 0.0   Gross profit growth   49.7% 47.3% 205.2% -28.7% 18.8% -23.0% -100.0% 0.0%   Employees   19 22 29 48 60 54 0 0   Employee growth %   0.0% 15.8% 31.8% 65.5% 25.0% -10.0% -100.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   30 34 74 88 103 100 79 79   Balance sheet change%   31.5% 14.5% 117.9% 18.3% 18.0% -3.7% -20.3% 0.0%   Added value   5.8 11.0 51.8 23.9 22.1 14.4 0.0 0.0   Added value %   20.9% 26.3% 49.9% 23.5% 18.7% 13.6% 0.0% 0.0%   Investments   -2 -2 -1 25 -13 -13 -41 0   Net sales trend   0.0 1.0 2.0 -1.0 1.0 -1.0 0.0 0.0   EBIT trend   1.0 2.0 3.0 4.0 5.0 5.0 0.0 0.0   1.0 Profitability  2018 2019/3 2019 2020/3 2020 2021/3 2021 2022/3 2022 2023/3 2023 2024/3 2024e N/A 2025e N/A EBITDA %   20.9% 26.3% 49.9% 23.5% 21.5% 13.6% 0.0% 0.0%   EBIT %   12.8% 20.0% 46.3% 17.0% 13.1% 3.3% 0.0% 0.0%   EBIT to gross profit (%)   22.7% 35.9% 67.8% 34.1% 25.7% 7.5% 0.0% 0.0%   Net Earnings %   13.5% 19.2% 34.3% 12.4% 9.9% 2.4% 0.0% 0.0%   Profit before depreciation and extraordinary items %   21.6% 25.6% 37.8% 19.0% 18.3% 12.7% 0.0% 0.0%   Pre tax profit less extraordinaries %   11.5% 19.2% 46.1% 15.8% 12.6% 3.1% 0.0% 0.0%   ROA %   13.7% 26.2% 89.1% 21.3% 16.2% 3.6% 0.0% 0.0%   ROI %   16.3% 33.2% 116.9% 26.7% 19.1% 4.3% 0.0% 0.0%   ROE %   50.6% 60.1% 101.2% 21.3% 16.4% 3.3% 0.0% 0.0%   1.0 Solidity  2018 2019/3 2019 2020/3 2020 2021/3 2021 2022/3 2022 2023/3 2023 2024/3 2024e N/A 2025e N/A Equity ratio %   31.5% 51.2% 71.6% 74.9% 74.8% 80.2% 100.0% 100.0%   Relative indebtedness %   72.8% 39.7% 18.6% 19.5% 20.9% 17.2% 0.0% 0.0%   Relative net indebtedness %   51.2% 29.4% -8.7% 12.5% 9.3% 1.5% -72.6% -72.6%   Net int. bear. debt to EBITDA, %   159.2% 29.1% -50.9% -10.3% -13.7% -100.2% 0.0% 0.0%   Gearing %   164.2% 43.3% 3.7% 7.2% 13.2% 2.7% 0.0% 0.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   2.5% 2.7% 5.2% 34.4% 8.3% 6.4% 0.0% 0.0%   1.0 Liquidity  2018 2019/3 2019 2020/3 2020 2021/3 2021 2022/3 2022 2023/3 2023 2024/3 2024e N/A 2025e N/A Quick Ratio   2.6 1.6 2.5 1.3 1.6 2.0 0.0 0.0   Current Ratio   3.0 1.9 2.9 1.9 2.3 3.1 0.0 0.0   Cash and cash equivalent   6.0 4.3 28.3 7.2 13.7 16.5 0.0 0.0   1.0 Capital use efficiency  2018 2019/3 2019 2020/3 2020 2021/3 2021 2022/3 2022 2023/3 2023 2024/3 2024e N/A 2025e N/A Trade debtors turnover (days)   46.2 62.4 58.5 38.9 55.0 22.0 0.0 0.0   Trade creditors turnover (days)   87.4 30.5 19.2 56.7 29.0 69.0 0.0 0.0   Current assets / Net sales %   53.8% 44.1% 53.9% 37.5% 48.3% 52.6% 72.6% 72.6%   Net working capital   10.1 8.8 36.6 18.2 32.4 37.4 0.0 0.0   Net working capital %   36.0% 21.0% 35.2% 17.9% 27.5% 35.4% 0.0% 0.0%   1.0 Employee efficiency  2018 2019/3 2019 2020/3 2020 2021/3 2021 2022/3 2022 2023/3 2023 2024/3 2024e N/A 2025e N/A Net sales / employee   1 2 4 2 2 2 0 0   Added value / employee   0 1 2 0 0 0 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   0 1 2 0 0 0 0 0   EBIT / employee   0 0 2 0 0 0 0 0   Net earnings / employee   0 0 1 0 0 0 0 0